SEARCH

… approvals for GLP-1 (Glucagon-Like Peptide-1) medications, such as Ozempic, Wegovy, Mounjaro, and Zepbound, is a long one.  These powerful drugs for patients with diabetes and obesity come at a price tag exceeding $10,000 per patient annually. But there are ways to optimize your GLP-1 strategy!  Employee demand for the drugs as an obesity treatment and their potential health benefits are likely behind the push. A recent Kaiser Foundation survey found that one in eight U.S. adults (roughly 12.5%) have used a GLP-1 agonist, and considerably more are interested and hoping their employers …

Viewpoints from Nick Favro Attracting and retaining top talent requires a strong employer brand and a competitive benefits package. The past decade has seen soaring healthcare costs, legislative complexities, and renewal pitfalls. This market puts immense pressure on companies to manage benefits costs without sacrificing employee satisfaction. Having the right partner alongside you is a must – you do not need to navigate this alone. Don’t be blindsided. Healthcare inflation impact is inevitable. Utilization and increased unit costs will likely impact your renewal, whether your plan is fully insured or self-funded. But there’s good news. Your EPIC broker …